Top of this page
Skip navigation, go straight to the content

Our Science UCB5857

Clinical Study Information - UCB5857

Disease area
studied
Abbreviated title Phase Study ID Registry database Study results Lay summary Publication (if available)
APDS
An Open-Label, Exploratory, Multicenter, Extension Study to Evaluate the Long-Term Safety, Tolerability, Pharmacokinetics and Efficacy of UCB5857 in Subjects with Activated Phosphoinositide 3 Kinase (PI3K) Delta Syndrome (APDS) Phase 3 APD003
Ongoing
 
2015-005541-30
Sjogren´s Syndrome  A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjorgen's Syndrome Phase 2 SS0004
Terminated
NCT02610543
2014-004523-51